NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Protagonist Therapeutics, Inc. PTGX
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$46.0M
▼ 89.4% vs FY2024
EPS · FY25
$-2.05
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-20.2%
Net margin · FY25
-282.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 46.0M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 283 cents on every revenue dollar this year.
Per share
USD -2.05
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-20.2%
Return on equity, FY2025
ROE
Operating margin-343.6%
Net margin-282.8%
Return on assets-18.4%
Each USD of equity lost 20 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+10.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+20.1%
+10.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+43.1%
Change, 10 years—
The share count grew 43% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 668.2M
total assets, end of FY2025
Total assetsUSD 668.2M
EquityUSD 614.7M
CashUSD 128.4M
Current ratio12.71×
Equity funds 92% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.4
0.1
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Operating income $B
−0.2
0.3
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.2
0.3
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
0.3
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.05
4.23
−1.39
−2.60
−2.71
−1.92
−2.98
−1.74
−2.09
−5.80
−59.32
−49.38
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−20.2
54.4
−28.6
−49.4
−43.3
−36.8
−80.2
−33.4
−35.5
−123.6
·
·
Shares out B
0.06
0.06
0.06
0.05
0.05
0.04
0.03
0.02
0.02
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed